comparemela.com

Latest Breaking News On - First advisors inc - Page 1 : comparemela.com

9,479 Shares in iShares Biotechnology ETF (NASDAQ:IBB) Bought by LM Advisors LLC

LM Advisors LLC bought a new position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 9,479 shares of the financial services provider’s stock, valued at approximately $1,288,000. Several other institutional investors have also […]

Exchange-commission
Elm-advisors
First-advisors-inc
Nasdaq-biotechnology-index-fund
Crewe-advisors
Nasdaq
Massmutual-trust-co
Shares-biotechnology
Free-report
Financial-advisors
First-advisors

Short Interest in 908 Devices Inc. (NASDAQ:MASS) Drops By 21.6%

908 Devices Inc. (NASDAQ:MASS – Get Free Report) was the target of a large decrease in short interest during the month of May. As of May 15th, there was short interest totalling 1,050,000 shares, a decrease of 21.6% from the April 30th total of 1,340,000 shares. Approximately 4.2% of the shares of the stock are […]

Florida
United-states
New-york
Kevinj-knopp
Devices-inc
Devices-company-profile
Nasdaq
York-state-common-retirement-fund
First-advisors-inc
York-mellon-corp
Sg-americas-securities

Citigroup Begins Coverage on Sage Therapeutics (NASDAQ:SAGE)

Citigroup initiated coverage on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a research note issued to investors on Wednesday, Marketbeat reports. The brokerage issued a sell rating and a $8.00 price target on the biopharmaceutical company’s stock. SAGE has been the subject of several other reports. The Goldman Sachs Group decreased their price […]

China
Morgan-stanley
Proshare-advisors
Virtu-financial
Lazard-asset-management
Citigroup
China-universal-asset-management-co
Goldman-sachs-group
Sage-therapeutics-inc
First-advisors-inc
Jpmorgan-chase-co

Sage Therapeutics (NASDAQ:SAGE) Raised to "Hold" at Baird R W

Baird R W upgraded shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) to a hold rating in a research note issued to investors on Wednesday, Zacks.com reports. A number of other analysts have also weighed in on the company. Wedbush reaffirmed a neutral rating and set a $24.00 price objective on shares of Sage Therapeutics […]

China
United-states
America
Goldman-sachs-group
First-advisors-inc
Canaccord-genuity-group
Lazard-asset-management
Virtu-financial
Quest-partners
Sage-therapeutics-company-profile
Sage-therapeutics-inc

Central Garden & Pet (NASDAQ:CENT) Shares Sold by Swiss National Bank

Swiss National Bank reduced its position in Central Garden & Pet (NASDAQ:CENT – Free Report) by 11.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,550 shares of the company’s stock after selling 2,300 shares during the period. Swiss […]

United-states
Louisiana
New-york
Switzerland
Swiss
Howard-machek
Johnd-walker
Swiss-national-bank
Central-garden-pet-company
Canaccord-genuity-group
Securities-exchange-commission
Nisa-investment-advisors

vimarsana © 2020. All Rights Reserved.